Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib

The study investigated cutaneous adverse effects in 14 patients treated with dabrafenib alone or in combination with trametinib for metastatic melanoma. All patients experienced at least one skin reaction, with the most common being papillomas (7/14), palmoplantar hyperkeratosis (5/14), alopecia (5/14), and seborrheic dermatitis-like eruptions (2/14). Three patients on trametinib developed acneiform eruptions, and one patient developed a keratoacanthoma-like squamous cell carcinoma. Side effects appeared as early as 2 weeks, with a mean onset of 9 weeks. The study highlighted the importance of monitoring and managing these adverse effects due to the potential for malignant lesions.